Illustrative image.
Combivir
Lamivudine and Zidovudine
$1827.00
300mg/150mg · 3 × 60 tablets · 3 months supply
BrandBranded medicine· By GSK
$609.00 per month
How long a supply?
Test mode: no payment is taken. View cart
Annual cost
$7308a year at this pack size
Prescription required
Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.
FDA boxed warningHematologic toxicity, myopathy, lactic acidosis and severe hepatomegaly with steatosis, and exacerbations of hepatitis b
Zidovudine, a component of COMBIVIR (lamivudine and zidovudine) tablets, has been associated with hematologic toxicity including neutropenia and severe anemia, particularly in patients with advanced Human Immunodeficiency Virus (HIV ‑ 1) disease.
Prolonged use of zidovudine has been associated with symptomatic myopathy.
Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues, including lamivudine and zidovudine (components of COMBIVIR). Discontinue COMBIVIR if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.
Severe acute exacerbations of hepatitis B have been reported in patients who are co ‑ infected with hepatitis B virus (HBV) and HIV ‑ 1 and have discontinued lamivudine, which is one component of COMBIVIR. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue COMBIVIR and are co ‑ infected with HIV ‑ 1 and HBV. If appropriate, initiation of anti-hepatitis B therapy may be warranted.
Hematologic toxicity, including neutropenia and anemia, has been associated with the use of zidovudine, a component of COMBIVIR.
Symptomatic myopathy associated with prolonged use of zidovudine.
Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues including lamivudine and zidovudine (components of COMBIVIR). Suspend treatment if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.
Severe acute exacerbations of hepatitis B have been reported in patients who are co-infected with hepatitis B virus (HBV) and human immunodeficiency virus (HIV ‑ 1) and have discontinued lamivudine, a component of COMBIVIR. Monitor hepatic function closely in these patients and, if appropriate, initiate anti-hepatitis B treatment.
About Combivir
Overview
Combivir is a prescription tablet containing lamivudine and zidovudine. It is used with other antiretroviral medicines to treat human immunodeficiency virus type 1 (HIV-1) infection. Its two ingredients act against HIV-1 as nucleoside analogue reverse transcriptase inhibitors.
What it treats
Treatment of human immunodeficiency virus type 1 (HIV-1) infection in combination with other antiretroviral medicines.
Safety information
Side effects
Common side effects include headache, nausea, feeling unwell, tiredness, nasal symptoms, diarrhea and cough. These were reported in at least 15% of people in clinical trials of lamivudine and zidovudine together. Serious side effects that warrant contacting a doctor include: • Anemia and low levels of neutrophils, a type of white blood cell. • Muscle disease. • Lactic acidosis, a buildup of lactic acid in the body, and severe liver enlargement with fat buildup. • Worsening hepatitis B. • Severe worsening of liver function, sometimes fatal, in people with both HIV-1 and hepatitis C receiving combination HIV treatment and interferon alfa, with or without ribavirin. • Worsening anemia in people with both HIV-1 and hepatitis C receiving ribavirin and zidovudine. Using these medicines together is not advised. • Pancreatitis, or inflammation of the pancreas. Caution is needed in people with a history of pancreatitis or other significant risk factors. • Immune reconstitution syndrome, an inflammatory reaction as the immune system recovers. • Loss of body fat, known as lipoatrophy.
FDA boxed warning
Hematologic toxicity, myopathy, lactic acidosis and severe hepatomegaly with steatosis, and exacerbations of hepatitis b
Zidovudine, a component of COMBIVIR (lamivudine and zidovudine) tablets, has been associated with hematologic toxicity including neutropenia and severe anemia, particularly in patients with advanced Human Immunodeficiency Virus (HIV ‑ 1) disease.
Prolonged use of zidovudine has been associated with symptomatic myopathy.
Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues, including lamivudine and zidovudine (components of COMBIVIR). Discontinue COMBIVIR if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.
Severe acute exacerbations of hepatitis B have been reported in patients who are co ‑ infected with hepatitis B virus (HBV) and HIV ‑ 1 and have discontinued lamivudine, which is one component of COMBIVIR. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue COMBIVIR and are co ‑ infected with HIV ‑ 1 and HBV. If appropriate, initiation of anti-hepatitis B therapy may be warranted.
Hematologic toxicity, including neutropenia and anemia, has been associated with the use of zidovudine, a component of COMBIVIR.
Symptomatic myopathy associated with prolonged use of zidovudine.
Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues including lamivudine and zidovudine (components of COMBIVIR). Suspend treatment if clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity occur.
Severe acute exacerbations of hepatitis B have been reported in patients who are co-infected with hepatitis B virus (HBV) and human immunodeficiency virus (HIV ‑ 1) and have discontinued lamivudine, a component of COMBIVIR. Monitor hepatic function closely in these patients and, if appropriate, initiate anti-hepatitis B treatment.
A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.
When to call your doctor
If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.
Before taking this medicine
Do not take Combivir if you have previously had an allergic reaction to lamivudine or zidovudine. Use with caution if you have a history of pancreatitis or other significant risk factors for pancreatitis. If you have both HIV-1 and hepatitis C and receive interferon alfa, with or without ribavirin, alongside combination HIV treatment, serious liver deterioration, sometimes fatal, has been reported. Your prescriber may need to change or stop treatment. Taking ribavirin with zidovudine is not advised because worsening anemia has been reported. Changes related to immune system recovery and loss of body fat have been reported with combination HIV treatment. Women with HIV should not breastfeed because HIV may be passed to the baby.
Interactions
Tell your doctor about medicines that work against zidovudine’s action, as they should not be used with Combivir. Medicines that suppress bone marrow, affect blood cell production or damage cells may increase zidovudine’s harmful effects on blood cells. Sorbitol may lower lamivudine levels. Regular, ongoing use with Combivir should be avoided when possible. Ask your doctor about any medicines or other products you use that contain sorbitol.
Using Combivir
Dosing
Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.
Storage
Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.
Clinical information on this page is summarised from the US FDA label COMBIVIR (LAMIVUDINE AND ZIDOVUDINE) TABLET, FILM COATED [VIIV HEALTHCARE COMPANY] (DailyMed, retrieved 19 September 2026).
Patient information and references
Official and supporting information to read alongside advice from your prescriber or pharmacist.
Reviews
No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.
- Every prescription order is checked by a licensed pharmacist before dispensing.
- Payment pages are encrypted and card details never reach our servers.
- We ship internationally, with cold-chain packing where a medicine needs it.
Related medicines
Ziagen
Abacavir
By GSK
Tablets · from 60 per pack
Also for antivirals
Brand $767.00
Baraclude
Enetecavir
By Bristol Myers
Tablets · from 30 per pack
Also for antivirals
Brand from $1,203.00
Isenrtess
Raltegravir
By MSD
Tablets · from 60 per pack
Also for antivirals
Brand $1,398.00
STRIBILD
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate
By Gilead Sciences
Tablets · from 30 per pack
Also for antivirals
Brand $1,405.00